DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 157 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $232,343 | -0.4% | 18,266 | +10.3% | 0.00% | – |
| Q2 2023 | $233,263 | -3.1% | 16,567 | +6.3% | 0.00% | – |
| Q1 2023 | $240,773 | +4.6% | 15,584 | +11.0% | 0.00% | – |
| Q4 2022 | $230,181 | +4.2% | 14,044 | +17.3% | 0.00% | – |
| Q3 2022 | $221,000 | +64.9% | 11,968 | +16.8% | 0.00% | – |
| Q2 2022 | $134,000 | -79.3% | 10,250 | -46.2% | 0.00% | – |
| Q3 2021 | $648,000 | -8.5% | 19,056 | -1.5% | 0.00% | – |
| Q2 2021 | $708,000 | -24.4% | 19,353 | -7.3% | 0.00% | -100.0% |
| Q1 2021 | $937,000 | -22.9% | 20,877 | -2.1% | 0.00% | 0.0% |
| Q4 2020 | $1,216,000 | +43.7% | 21,315 | +29.2% | 0.00% | 0.0% |
| Q3 2020 | $846,000 | -17.8% | 16,495 | -4.3% | 0.00% | 0.0% |
| Q2 2020 | $1,029,000 | +229.8% | 17,235 | +127.7% | 0.00% | – |
| Q1 2020 | $312,000 | -29.9% | 7,568 | +5.7% | 0.00% | – |
| Q4 2019 | $445,000 | – | 7,157 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 1,209,571 | $72,236,000 | 20.73% |
| SV Health Investors, LLC | 449,951 | $26,871,000 | 18.64% |
| Redmile Group, LLC | 4,978,941 | $297,342,000 | 5.49% |
| Sunesis Advisors, LLC | 96,299 | $5,751,000 | 5.29% |
| Eversept Partners, LP | 418,652 | $25,001,897 | 3.43% |
| Opaleye Management Inc. | 222,000 | $13,081,000 | 2.64% |
| Avoro Capital Advisors LLC | 1,860,000 | $111,079,000 | 2.20% |
| SPHERA FUNDS MANAGEMENT LTD. | 282,965 | $16,899,000 | 1.59% |
| SECTORAL ASSET MANAGEMENT INC | 224,359 | $13,399,000 | 1.23% |
| Artal Group S.A. | 650,000 | $38,818,000 | 1.09% |